Access clinical evidence, training resources, marketing tools, and dedicated support, all in one place.
Book a Demo
Recommended Actions For You
I'm a Distributor / Partner
Recommended Actions For You
CE Certified
ISO 13485
Made in Europe
Patented Technology
Registered with 30+ Authorities
Everything you need to get started with Regenera Activa.
Lorem is The Leading Dermatology & Laser Event in the Middle East, Africa Market and Beyond. Celebrate an important milestone with us as Regenera Activa marks 10 years of innovation in regenerative medicine. Unmatched opportunity to network with distinguished experts and interact with peers from across the globe, helping you to…
What's New
View More
Past Webinar
View More
Dubai Derma 2026
View More
Regenera 10th Years Anniversary
View More
3rd Barcelona Hair Meeting
Regenera Activa introduces an innovative approach to regenerative treatment for AGA with our patented medical device, engineered to obtain an injectable autologous micrograft solution called AMT® Triad. This solution contains progenitor cells, extracellular matrix components, and extracellular vesicles derived from autologous tissue. It is obtained from a healthy scalp tissue sample typically harvested from the retroauricular region.
Utilizing a mechanical disaggregation process, the biopsies are transformed into a solution that is then injected into areas with impaired or damaged tissue. This approach is designed to support the biological processes involved in hair follicle regeneration, harnessing the patient’s own tissue components to support natural hair growth.
The entire procedure, including biopsies obtention, disaggregation and ingrafting, takes approximately 30 minutes. Clinical studies have reported improvements in hair parameters following a single treatment session, while the autologous and minimally manipulated nature of the procedure contributes to a favorable safety profile.
Clinical evidence has demonstrated improvements in hair density and thickness, supporting the use of autologous micrografts as part of a comprehensive treatment strategy for androgenetic alopecia.
We’ve precisely quantified up to 70 billions* Human Smart Exosomes in our AMT® Triad. This breakthrough confirms their autologous nature and tissue-specific function, offering personalized regeneration.
These extracellular vesicles carry biological signals derived from the patient’s own tissue, supporting individualized regenerative processes.
Quantity depending on the protocol applied and patient variables.
Download Exosomes Trifold
Latest Blogs
Our sales and medical teams are organized by region. Select your country and we’ll route you to the right contact.
